Click for best price
Chronic Granulomatous Disease CGD Treatment Market Size, Share 2024
The global Chronic Granulomatous Disease (CGD) Treatment market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
X-Linked Chronic Granulomatous Disease Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Chronic Granulomatous Disease (CGD) Treatment include Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG and Lonza, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Granulomatous Disease (CGD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Granulomatous Disease (CGD) Treatment. This report contains market size and forecasts of Chronic Granulomatous Disease (CGD) Treatment in global, including the following market information:
Global Chronic Granulomatous Disease (CGD) Treatment Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We has surveyed the Chronic Granulomatous Disease (CGD) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chronic Granulomatous Disease (CGD) Treatment Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Chronic Granulomatous Disease (CGD) Treatment Market Segment Percentages, by Type, 2023 (%)
X-Linked Chronic Granulomatous Disease
Autosomal Recessive Chronic Granulomatous Disease
Global Chronic Granulomatous Disease (CGD) Treatment Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Chronic Granulomatous Disease (CGD) Treatment Market Segment Percentages, by Application, 2023 (%)
Neutrophil Function Tests
Genetic Testing
Prenatal Testing
Global Chronic Granulomatous Disease (CGD) Treatment Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Chronic Granulomatous Disease (CGD) Treatment Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chronic Granulomatous Disease (CGD) Treatment revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Chronic Granulomatous Disease (CGD) Treatment revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Clinigen Group plc
Orchard Therapeutics plc2032
Horizon Therapeutics plc
ViroMed. Co. Ltd
Bellicum Pharmaceuticals, Inc
Pfizer Inc
Hoffmann-La Roche Ltd
Novartis AG
Lonza
GlaxoSmithKline plc
Eli Lilly and Company
Johnson & Johnson Services, Inc
Merck KGaA
Outline of Major Chapters:
Chapter 1: Introduces the definition of Chronic Granulomatous Disease (CGD) Treatment, market overview.
Chapter 2: Global Chronic Granulomatous Disease (CGD) Treatment market size in revenue.
Chapter 3: Detailed analysis of Chronic Granulomatous Disease (CGD) Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chronic Granulomatous Disease (CGD) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Chronic Granulomatous Disease (CGD) Treatment Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
60 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Chronic Granulomatous Disease (CGD) Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chronic Granulomatous Disease (CGD) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Chronic Granulomatous Disease (CGD) Treatment Overall Market Size
2.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Size: 2023 VS 2030
2.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Chronic Granulomatous Disease (CGD) Treatment Players in Global Market
3.2 Top Global Chronic Granulomatous Disease (CGD) Treatment Companies Ranked by Revenue
3.3 Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Companies
3.4 Top 3 and Top 5 Chronic Granulomatous Disease (CGD) Treatment Companies in Global Market, by Revenue in 2023
3.5 Global Companies Chronic Granulomatous Disease (CGD) Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Granulomatous Disease (CGD) Treatment Players in Global Market
3.6.1 List of Global Tier 1 Chronic Granulomatous Disease (CGD) Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Chronic Granulomatous Disease (CGD) Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Chronic Granulomatous Disease (CGD) Treatment Market Size Markets, 2023 & 2030
4.1.2 X-Linked Chronic Granulomatous Disease
4.1.3 Autosomal Recessive Chronic Granulomatous Disease
4.2 By Type - Global Chronic Granulomatous Disease (CGD) Treatment Revenue & Forecasts
4.2.1 By Type - Global Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2024
4.2.2 By Type - Global Chronic Granulomatous Disease (CGD) Treatment Revenue, 2025-2030
4.2.3 By Type - Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Chronic Granulomatous Disease (CGD) Treatment Market Size, 2023 & 2030
5.1.2 Neutrophil Function Tests
5.1.3 Genetic Testing
5.1.4 Prenatal Testing
5.2 By Application - Global Chronic Granulomatous Disease (CGD) Treatment Revenue & Forecasts
5.2.1 By Application - Global Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2024
5.2.2 By Application - Global Chronic Granulomatous Disease (CGD) Treatment Revenue, 2025-2030
5.2.3 By Application - Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Chronic Granulomatous Disease (CGD) Treatment Market Size, 2023 & 2030
6.2 By Region - Global Chronic Granulomatous Disease (CGD) Treatment Revenue & Forecasts
6.2.1 By Region - Global Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2024
6.2.2 By Region - Global Chronic Granulomatous Disease (CGD) Treatment Revenue, 2025-2030
6.2.3 By Region - Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2030
6.3.2 US Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.3.3 Canada Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.3.4 Mexico Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2030
6.4.2 Germany Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.4.3 France Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.4.4 U.K. Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.4.5 Italy Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.4.6 Russia Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.4.7 Nordic Countries Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.4.8 Benelux Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2030
6.5.2 China Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.5.3 Japan Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.5.4 South Korea Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.5.5 Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.5.6 India Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2030
6.6.2 Brazil Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.6.3 Argentina Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2030
6.7.2 Turkey Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.7.3 Israel Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.7.4 Saudi Arabia Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
6.7.5 UAE Chronic Granulomatous Disease (CGD) Treatment Market Size, 2019-2030
7 Chronic Granulomatous Disease (CGD) Treatment Companies Profiles
7.1 Clinigen Group plc
7.1.1 Clinigen Group plc Company Summary
7.1.2 Clinigen Group plc Business Overview
7.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.1.4 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.1.5 Clinigen Group plc Key News & Latest Developments
7.2 Orchard Therapeutics plc2032
7.2.1 Orchard Therapeutics plc2032 Company Summary
7.2.2 Orchard Therapeutics plc2032 Business Overview
7.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.2.4 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.2.5 Orchard Therapeutics plc2032 Key News & Latest Developments
7.3 Horizon Therapeutics plc
7.3.1 Horizon Therapeutics plc Company Summary
7.3.2 Horizon Therapeutics plc Business Overview
7.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.3.4 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.3.5 Horizon Therapeutics plc Key News & Latest Developments
7.4 ViroMed. Co. Ltd
7.4.1 ViroMed. Co. Ltd Company Summary
7.4.2 ViroMed. Co. Ltd Business Overview
7.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.4.4 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.4.5 ViroMed. Co. Ltd Key News & Latest Developments
7.5 Bellicum Pharmaceuticals, Inc
7.5.1 Bellicum Pharmaceuticals, Inc Company Summary
7.5.2 Bellicum Pharmaceuticals, Inc Business Overview
7.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.5.4 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.5.5 Bellicum Pharmaceuticals, Inc Key News & Latest Developments
7.6 Pfizer Inc
7.6.1 Pfizer Inc Company Summary
7.6.2 Pfizer Inc Business Overview
7.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.6.4 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.6.5 Pfizer Inc Key News & Latest Developments
7.7 Hoffmann-La Roche Ltd
7.7.1 Hoffmann-La Roche Ltd Company Summary
7.7.2 Hoffmann-La Roche Ltd Business Overview
7.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.7.4 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.7.5 Hoffmann-La Roche Ltd Key News & Latest Developments
7.8 Novartis AG
7.8.1 Novartis AG Company Summary
7.8.2 Novartis AG Business Overview
7.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.8.4 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.8.5 Novartis AG Key News & Latest Developments
7.9 Lonza
7.9.1 Lonza Company Summary
7.9.2 Lonza Business Overview
7.9.3 Lonza Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.9.4 Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.9.5 Lonza Key News & Latest Developments
7.10 GlaxoSmithKline plc
7.10.1 GlaxoSmithKline plc Company Summary
7.10.2 GlaxoSmithKline plc Business Overview
7.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.10.4 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.10.5 GlaxoSmithKline plc Key News & Latest Developments
7.11 Eli Lilly and Company
7.11.1 Eli Lilly and Company Company Summary
7.11.2 Eli Lilly and Company Business Overview
7.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.11.4 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.11.5 Eli Lilly and Company Key News & Latest Developments
7.12 Johnson & Johnson Services, Inc
7.12.1 Johnson & Johnson Services, Inc Company Summary
7.12.2 Johnson & Johnson Services, Inc Business Overview
7.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.12.4 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.12.5 Johnson & Johnson Services, Inc Key News & Latest Developments
7.13 Merck KGaA
7.13.1 Merck KGaA Company Summary
7.13.2 Merck KGaA Business Overview
7.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Major Product Offerings
7.13.4 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue in Global Market (2019-2024)
7.13.5 Merck KGaA Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Chronic Granulomatous Disease (CGD) Treatment Market Opportunities & Trends in Global Market
Table 2. Chronic Granulomatous Disease (CGD) Treatment Market Drivers in Global Market
Table 3. Chronic Granulomatous Disease (CGD) Treatment Market Restraints in Global Market
Table 4. Key Players of Chronic Granulomatous Disease (CGD) Treatment in Global Market
Table 5. Top Chronic Granulomatous Disease (CGD) Treatment Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Share by Companies, 2019-2024
Table 8. Global Companies Chronic Granulomatous Disease (CGD) Treatment Product Type
Table 9. List of Global Tier 1 Chronic Granulomatous Disease (CGD) Treatment Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chronic Granulomatous Disease (CGD) Treatment Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Chronic Granulomatous Disease (CGD) Treatment Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Chronic Granulomatous Disease (CGD) Treatment Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Chronic Granulomatous Disease (CGD) Treatment Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Chronic Granulomatous Disease (CGD) Treatment Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2025-2030
Table 30. Clinigen Group plc Company Summary
Table 31. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 32. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 33. Clinigen Group plc Key News & Latest Developments
Table 34. Orchard Therapeutics plc2032 Company Summary
Table 35. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 36. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 37. Orchard Therapeutics plc2032 Key News & Latest Developments
Table 38. Horizon Therapeutics plc Company Summary
Table 39. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 40. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 41. Horizon Therapeutics plc Key News & Latest Developments
Table 42. ViroMed. Co. Ltd Company Summary
Table 43. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 44. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 45. ViroMed. Co. Ltd Key News & Latest Developments
Table 46. Bellicum Pharmaceuticals, Inc Company Summary
Table 47. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 48. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 49. Bellicum Pharmaceuticals, Inc Key News & Latest Developments
Table 50. Pfizer Inc Company Summary
Table 51. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 52. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 53. Pfizer Inc Key News & Latest Developments
Table 54. Hoffmann-La Roche Ltd Company Summary
Table 55. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 56. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 57. Hoffmann-La Roche Ltd Key News & Latest Developments
Table 58. Novartis AG Company Summary
Table 59. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 60. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 61. Novartis AG Key News & Latest Developments
Table 62. Lonza Company Summary
Table 63. Lonza Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 64. Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 65. Lonza Key News & Latest Developments
Table 66. GlaxoSmithKline plc Company Summary
Table 67. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 68. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 69. GlaxoSmithKline plc Key News & Latest Developments
Table 70. Eli Lilly and Company Company Summary
Table 71. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 72. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 73. Eli Lilly and Company Key News & Latest Developments
Table 74. Johnson & Johnson Services, Inc Company Summary
Table 75. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 76. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 77. Johnson & Johnson Services, Inc Key News & Latest Developments
Table 78. Merck KGaA Company Summary
Table 79. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Product Offerings
Table 80. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue (US$, Mn) & (2019-2024)
Table 81. Merck KGaA Key News & Latest Developments
List of Figures
Figure 1. Chronic Granulomatous Disease (CGD) Treatment Segment by Type in 2023
Figure 2. Chronic Granulomatous Disease (CGD) Treatment Segment by Application in 2023
Figure 3. Global Chronic Granulomatous Disease (CGD) Treatment Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Chronic Granulomatous Disease (CGD) Treatment Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Chronic Granulomatous Disease (CGD) Treatment Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chronic Granulomatous Disease (CGD) Treatment Revenue in 2023
Figure 8. By Type - Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 9. By Application - Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 10. By Type - Global Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 12. By Application - Global Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 14. By Region - Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 15. By Country - North America Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 16. US Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 20. Germany Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 21. France Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 28. China Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 32. India Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 34. Brazil Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share, 2019-2030
Figure 37. Turkey Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Chronic Granulomatous Disease (CGD) Treatment Revenue, (US$, Mn), 2019-2030
Figure 41. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
